Skip to content
Peptide drugs targeting unmet medical needs

About Tarix Pharmaceuticals

Tarix Pharmaceuticals is a clinical stage biopharmaceutical company developing peptide drugs, TXA127 and TXA302, to address significant unmet medical needs. These peptides are components of the ACE2/Angiotensin (1-7)/Mas pathway in the renin angiotensin system (RAS). We are investigating the use of the peptides in two principal therapeutic areas:

  • TXA302 for Ischemic Diseases: Post-ischemic Functional Deficit (PIFD), peripheral vascular disease, type 2 diabetes. More information can be found at www.tarixcvm.com.
  • TXA127 for Orphan Diseases: muscular dystrophies, Marfan syndrome. More information can be found at www.tarixorphan.com.

Comments are closed.